Aarti Drugs jumps on buzz DGTR recommends anti-dumping duty on Ofloxacin

17 Aug 2022 , 09:57 AM

Ofloxacin is a quinolone antibiotic useful for the treatment of a number of bacterial infections. Aarti Drugs had earlier filed an application for anti-dumping duty on Ofloxacin and its intermediates imported from China. Following the application, an anti-dumping investigation concerning imports of Ofloxacin and its intermediates originating in or exported from China PR was initiated on 17 September 2021 under the Customs Tariff (Identification, Assessment and Collection of Anti-dumping duty on Dumped Articles and for Determination of Injury) Rules, 1995 (AD Rules). DGTR has reportedly completed investigation on the application of Aarti Drugs and has recommended continuation of anti-dumping duty on Ofloxacin and its intermediates imported from China. Aarti Drugs is primarily involved in manufacturing and marketing of active pharmaceutical ingredients (API), pharma intermediates and specialty chemicals. On a consolidated basis, net profit of Aarti Drugs declined 28.72% to Rs 34.79 crore on 7.24% rise in net sales to Rs 621.96 crore in Q1 June 2022 over Q1 June 2021. Powered by Capital Market – Live News